Koronis in the News

From Soup to Nuts
Drug Discovery & Development, April 01, 2008

Why Are Evolutionary Biologists Bringing Back Extinct Deadly Viruses?
The New Yorker, Annals of Science, Darwin’s Surprise, December 3, 2007

New Kind of Antiretroviral, KP-1461; Clinical Trial Recruiting
AIDS Treatment News, October 11, 2007

KP-1461 Novel Agent Enters Phase 2a Proof-of-Concept Study
Positively Aware, September/October 2007

2008 Press Releases

Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development (February 7, 2008) READ MORE >>

Koronis Pharmaceuticals Announces Appointment of Daniel H. Petree and George R. Painter, Ph.D. to Board of Directors (January 31, 2008) READ MORE >>

2007 Press Releases

Koronis Pharmaceuticals Announces Issuance of U.S. Patent for KP-1461 Therapeutic in Development for Treatment of HIV (July 23, 2007) READ MORE >>

Koronis Pharmaceuticals Raises $20 Million -- Series D to Fund Phase 2 Proof-of-Concept Trials of HIV Therapeutic (June 28, 2007) READ MORE >>

Koronis Pharmaceuticals Begins Phase 2a Proof of Concept Study of KP-1461, a Novel, Viral Decay Acceleration™ Agent for HIV Infection (June 26, 2007) READ MORE >>

Koronis Pharmaceuticals Receives Notice of Allowance on Patent for Novel Therapeutic KP-1461 in Development for Treatment of HIV (April 19, 2007) READ MORE >>

Koronis Presents at the Invest Northwest CEO & Investor Forum in Seattle (March 21, 2007)

Koronis Completes Planned Enrollment in Phase 1b Clinical Study of KP-1461 in Treatment Experienced HIV Positive Patients; FDA Allows Additional Cohort of Patients to be Enrolled at Higher Dose (March 7, 2007)

Koronis Presents at BIO CEO & Investor Conference 2007 in New York (February 14, 2007)

Stay Informed

To keep updated on Koronis' latest events and news releases, please send an email to Julie@rathbuncomm.com to be added to our email news distribution list.